Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells

Clinical Immunology

Volumn 149, Issue 1, 2013, Pages 55-64

  Liu, Daofeng ^a,b   Song, Liping ^a,b   Brawley, Vita S ^a,b   Robison, Nathan ^c   Wei, Jie ^a,b   Gao, Xiuhua ^a,b   Tian, Gengwen ^a,b   Margol, Ashley ^c   Ahmed, Nabil ^a,b   Asgharzadeh, Shahab ^c   Metelitsa, Leonid S ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Brain tumors; CD1d; Cellular immunotherapy; Medulloblastoma; NKT cells

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 4; MESSENGER RNA; SONIC HEDGEHOG PROTEIN;

ADOLESCENT; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER MODEL; CHILD; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE PRODUCTION; EX VIVO STUDY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPHOCYTOTOXICITY; MEDULLOBLASTOMA; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; T LYMPHOCYTE ACTIVATION; TUMOR XENOGRAFT;

BRAIN TUMORS; CD1D; CELLULAR IMMUNOTHERAPY; MEDULLOBLASTOMA; NKT CELLS;

ADOLESCENT; ANIMALS; ANTIGENS, CD1D; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNOTHERAPY; MALE; MEDULLOBLASTOMA; MICE; MICE, SCID; NATURAL KILLER T-CELLS; RNA, MESSENGER;

EID: 84880952431     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.06.005     Document Type: Article

References (37)

1. Packer R.J., Gajjar A., Vezina G., Rorke-Adams L., Burger P.C., Robertson P.L., et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J. Clin. Oncol. 2006, 24:4202-4208.
2. Kim W., Choy W., Dye J., Nagasawa D., Safaee M., Fong B., et al. The tumor biology and molecular characteristics of medulloblastoma identifying prognostic factors associated with survival outcomes and prognosis. J. Clin. Neurosci. 2011, 18:886-890.
3. Sadighi Z., Vats T., Khatua S. Childhood medulloblastoma: the paradigm shift in molecular stratification and treatment profile. J. Child Neurol. 2012, 10:1302-1307.
4. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114:97-109.
5. Thompson M.C., Fuller C., Hogg T.L., Dalton J., Finkelstein D., Lau C.C., et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J. Clin. Oncol. 2006, 24:1924-1931.
6. Cho Y.J., Tsherniak A., Tamayo P., Santagata S., Ligon A., Greulich H., et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J. Clin. Oncol. 2011, 29:1424-1430.
7. Taylor M.D., Northcott P.A., Korshunov A., Remke M., Cho Y.J., Clifford S.C., et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012, 123:465-472.
8. Kool M., Korshunov A., Remke M., Jones D.T., Schlanstein M., Northcott P.A., et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012, 123:473-484.
9. Northcott P.A., Shih D.J., Peacock J., Garzia L., Morrissy A.S., Zichner T., et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 2012, 488:49-56.
10. Pugh T.J., Weeraratne S.D., Archer T.C., Pomeranz Krummel D.A., Auclair D., Bochicchio J., et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 2012, 488:106-110.
11. Stastny M.J., Brown C.E., Ruel C., Jensen M.C. Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells. J. Pediatr. Hematol. Oncol. 2007, 29:669-677.
12. Ahmed N., Ratnayake M., Savoldo B., Perlaky L., Dotti G., Wels W.S., et al. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 2007, 67:5957-5964.
13. Kronenberg M., Gapin L. The unconventional lifestyle of NKT cells. Nat. Rev. Immunol. 2002, 2:557-568.
14. Dhodapkar M.V. Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges. Front. Biosci. 2009, 14:796-807.
15. Metelitsa L.S., Naidenko O.V., Kant A., Wu H.W., Loza M.J., Perussia B., et al. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J. Immunol. 2001, 167:3114-3122.
16. Patel O., Pellicci D.G., Gras S., Sandoval-Romero M.L., Uldrich A.P., Mallevaey T., et al. Recognition of CD1d-sulfatide mediated by a type II natural killer T cell antigen receptor. Nat. Immunol. 2012, 13:857-863.
17. Ulanova M., Tarkowski A., Porcelli S.A., Hanson L.A. Antigen-specific regulation of CD1 expression in humans. J. Clin. Immunol. 2000, 20:203-211.
18. Metelitsa L.S., Weinberg K.I., Emanuel P.D., Seeger R.C. Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia 2003, 17:1068-1077.
19. Fais F., Tenca C., Cimino G., Coletti V., Zanardi S., Bagnara D., et al. CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis. Leukemia 2005, 19:551-556.
20. Dhodapkar K.M., Cirignano B., Chamian F., Zagzag D., Miller D.C., Finlay J.L., et al. Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion. Int. J. Cancer 2004, 109:893-899.
21. Nowak M., Arredouani M.S., Tun-Kyi A., Schmidt-Wolf I., Sanda M.G., Balk S.P., et al. Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with alpha-galactosylceramide. PLoS One 2010, 5:e11311.
22. Metelitsa L.S., Wu H.W., Wang H., Yang Y., Warsi Z., Asgharzadeh S., et al. Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J. Exp. Med. 2004, 199:1213-1221.
23. Li X., Fujio M., Imamura M., Wu D., Vasan S., Wong C.H., et al. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:13010-13015.
24. Brennan P.J., Tatituri R.V., Brigl M., Kim E.Y., Tuli A., Sanderson J.P., et al. Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals. Nat. Immunol. 2011, 12:1202-1211.
25. Yanagisawa K., Seino K., Ishikawa Y., Nozue M., Todoroki T., Fukao K. Impaired proliferative response of V alpha 24 NKT cells from cancer patients against alpha-galactosylceramide. J. Immunol. 2002, 168:6494-6499.
26. Tahir S.M., Cheng O., Shaulov A., Koezuka Y., Bubley G.J., Wilson S.B., et al. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J. Immunol. 2001, 167:4046-4050.
27. Crowe N.Y., Coquet J.M., Berzins S.P., Kyparissoudis K., Keating R., Pellicci D.G., et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J. Exp. Med. 2005, 202:1279-1288.
28. Baev D.V., Peng X.H., Song L., Barnhart J.R., Crooks G.M., Weinberg K.I., et al. Distinct homeostatic requirements of CD4+ and CD4- subsets of Valpha24-invariant natural killer T cells in humans. Blood 2004, 104:4150-4156.
29. Salsman V.S., Chow K.K., Shaffer D.R., Kadikoy H., Li X.N., Gerken C., et al. Crosstalk between medulloblastoma cells and endothelium triggers a strong chemotactic signal recruiting T lymphocytes to the tumor microenvironment. PLoS One 2011, 6:e20267.
30. Jacobsen P.F., Jenkyn D.J., Papadimitriou J.M. Establishment of a human medulloblastoma cell line and its heterotransplantation into nude mice. J. Neuropathol. Exp. Neurol. 1985, 44:472-485.
31. Langdon J.A., Lamont J.M., Scott D.K., Dyer S., Prebble E., Bown N., et al. Combined genome-wide allelotyping and copy number analysis identify frequent genetic losses without copy number reduction in medulloblastoma. Genes Chromosomes Cancer 2006, 45:47-60.
32. Friedman H.S., Burger P.C., Bigner S.H., Trojanowski J.Q., Brodeur G.M., He X.M., et al. Phenotypic and genotypic analysis of a human medulloblastoma cell line and transplantable xenograft (D341 Med) demonstrating amplification of c-myc. Am. J. Pathol. 1988, 130:472-484.
33. Friedman H.S., Burger P.C., Bigner S.H., Trojanowski J.Q., Wikstrand C.J., Halperin E.C., et al. Establishment and characterization of the human medulloblastoma cell line and transplantable xenograft D283 Med. J. Neuropathol. Exp. Neurol. 1985, 44:592-605.
34. Siu I.M., Lal A., Blankenship J.R., Aldosari N., Riggins G.J. c-Myc promoter activation in medulloblastoma. Cancer Res. 2003, 63:4773-4776.
35. Futerman A.H. Distinct roles for sphingolipids and glycosphingolipids at different stages of neuronal development. Acta Biochim. Pol. 1998, 45:469-478.
36. Dhodapkar M.V., Geller M.D., Chang D.H., Shimizu K., Fujii S.I., Dhodapkar K.M., et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J. Exp. Med. 2003, 197:1667-1676.
37. Ishikawa E., Tsuboi K., Saijo K., Harada H., Takano S., Nose T., et al. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res. 2004, 24:1861-1871.